title: Effects of sitagliptin on plasma incretin concentrations after glucose administration through an esophagostomy tube or feeding in healthy cats.
abstract: We investigated the effect of sitagliptin, a dipeptidyl peptidase 4 inhibitor, on plasma incretin concentrations after glucose administration through an esophagostomy tube or feeding in healthy cats. Six cats were used for the glucose administration experiment and 5 cats were used for the feeding experiment. Glucose administration through an esophagostomy tube increased plasma glucagon-like peptide 1 (GLP-1) concentrations by 6-fold, whereas plasma glucose-dependent insulinotropic polypeptide (GIP) concentrations did not change. Feeding increased both plasma GLP-1 concentrations by 1.5-fold and GIP concentrations by 4.6-fold. Sitagliptin was administered through an esophagostomy tube (25 and 50 mg per cat) in the glucose administration experiment and orally (25 mg per cat) in the feeding experiment. Sitagliptin treatment potentiated the GLP-1 response to glucose by 1.5-fold (P < 0.05). In addition, postprandial plasma GLP-1 concentration was higher by 2-fold when sitagliptin was administered (P < 0.05). In contrast, administration of sitagliptin did not affect plasma GIP concentrations after glucose administration or feeding. Sitagliptin enhanced insulin secretion following glucose administration by 1.5-fold (P < 0.05); however, it did not influence the plasma glucose concentration. Furthermore, sitagliptin had no effect on the postprandial plasma glucose and insulin concentrations. In conclusion, this study provides no evidence that sitagliptin is beneficial for management of feline diabetes mellitus.
authors.affiliation: Laboratory of Veterinary Internal Medicine, Faculty of Applied Biological Sciences, Gifu University, Gifu 501-1193, Japan. Electronic address: nishii@gifu-u.ac.jp.
authors.forename: N
authors.initials: N
authors.lastname: Nishii
authors.affiliation: Laboratory of Veterinary Internal Medicine, Faculty of Applied Biological Sciences, Gifu University, Gifu 501-1193, Japan.
authors.forename: S
authors.initials: S
authors.lastname: Takashima
authors.affiliation: Laboratory of Veterinary Internal Medicine, Faculty of Agriculture, Tottori University, Tottori 680-8553, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Iguchi
authors.affiliation: Laboratory of Veterinary Internal Medicine, Faculty of Agriculture, Tottori University, Tottori 680-8553, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Murahata
authors.affiliation: Laboratory of Veterinary Internal Medicine, Faculty of Agriculture, Tottori University, Tottori 680-8553, Japan.
authors.forename: A
authors.initials: A
authors.lastname: Matsuu
authors.affiliation: Laboratory of Veterinary Internal Medicine, Faculty of Agriculture, Tottori University, Tottori 680-8553, Japan.
authors.forename: Y
authors.initials: Y
authors.lastname: Hikasa
authors.affiliation: Laboratory of Veterinary Internal Medicine, Faculty of Applied Biological Sciences, Gifu University, Gifu 501-1193, Japan.
authors.forename: H
authors.initials: H
authors.lastname: Kitagawa
mesh_terms: D000284:Administration, Oral; D000821:Animal Feed / Q000032:analysis; D000818:Animals; D002415:Cats / Q000097:blood* / Q000502:physiology; D004946:Esophagostomy; D005260:Female; D005749:Gastric Inhibitory Polypeptide / Q000235:genetics / Q000378:metabolism; D052216:Glucagon-Like Peptide 1 / Q000097:blood / Q000378:metabolism; D005947:Glucose / Q000008:administration & dosage / Q000494:pharmacology*; D054795:Incretins / Q000097:blood* / Q000235:genetics / Q000378:metabolism; D008297:Male; D011719:Pyrazines / Q000008:administration & dosage / Q000494:pharmacology*; D000068900:Sitagliptin Phosphate; D014230:Triazoles / Q000008:administration & dosage / Q000494:pharmacology*
chemical_list: D054795:Incretins; D011719:Pyrazines; D014230:Triazoles; D005749:Gastric Inhibitory Polypeptide; D052216:Glucagon-Like Peptide 1; D005947:Glucose; D000068900:Sitagliptin Phosphate
keywords: Feline; Glucagon-like peptide 1; Glucose-dependent insulinotropic polypeptide; Incretin; Sitagliptin